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Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. J
Thorac Oncol 2006;1:506–512.
In the article that appeared on page 506 of the June 2006 issue, the author line and the Table of Contents should have listed the authors as follows:
Pasi A. Ja¨nne, MD, PhD, Antoinette J. Wosniak, MD, Chandra P. Belani, MD, Mary-Louise Keohan, MD, Helen J. Ross, MD, Jonathan A.
Polikoff, MD, David M. Mintzer, MD, Zhishen Ye, PhD, Matthew J. Monberg, MS, and Coleman K. Obasaju, MD, PhD, on behalf of pemetrexed
expanded access program investigators. Please refer to the journal web site at www.jto.org for the final corrected version of this article. The citation
for this article remains the same. The Editor regrets this error.
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